Searched for
SAROGLITAZAR DRUG
Wockhardt secures US FDA approval for antibiotic ZaynichWockhardt's novel antibiotic, Zaynich (cefepime and zidebactam), has received US FDA approval for complicated urinary tract infections. Thi...- Stocks in news: RIL, Coal India, IDFC First Bank, Zydus Life, ONGCMarkets traded subdued with the India VIX correcting nearly 15% this week, though this hasn't significantly impacted benchmark index moveme...
- Zydus Therapeutics' saroglitazar drug granted priority review by US FDAZydus Therapeutics' drug saroglitazar has received priority review from the US FDA. This drug treats primary biliary cholangitis, a liver d...
- Zydus Saroglitazar shows positive Phase 3 results in rare liver disease PBC, US filing planned in 2026Zydus Therapeutics reveals encouraging outcomes from Saroglitazar's clinical trial. The drug targets Primary Biliary Cholangitis. The EPICS...
- Zydus aims to launch first new drug in US by early 2026Zydus will enter a competitive field, with an FDA decision on CymaBay's PBC drug due in August. Gilead Sciences announced its acquisition o...
- Torrent, Zydus in co-marketing pact for liver disease drug SaroglitazarTorrent Pharmaceuticals and Zydus Lifesciences formed a licensing and supply pact to co-market Saroglitazar Mg, the sole approved treatment...
- Zydus, Lupin enter licensing pact to market drug to treat liver diseaseZydus launched the drug under the brand names Lipaglyn and Bilypsa and will continue to market them. Lupin will pay Zydus upfront licensing...
- Lupin, Zydus Lifesciences ink licensing, supply pact for Saroglitazar MgLupin and Zydus Lifesciences entered into a licensing and supply agreement to co-market Saroglitazar Mg, an innovative drug approved by Ind...
- European Medicines Agency grants Orphan Drug Designation to Zydus Cadila's Saroglitazar MgOrphan Drug status in Europe is given to medicines with the potential to be safe and effective treatments for rare, life-threatening, or ch...
- USFDA grants orphan drug designation to Zydus Cadila's Saroglitazar MgZydus Cadila, which is a part of Cadila Group, said orphan drug designation provides eligibility for certain development incentives, includ...
- Zydus Cadila receives DCGI nod for NAFLD drug Saroglitazar Mg in IndiaNon-Alcoholic Fatty Liver Disease (NAFLD) is a progressive disease of the liver, which starts with fat accumulation in the liver in patient...
- Zydus Cadila gets USFDA Fast Track Designation for SaroglitazarDrug firm Zydus Cadila on Wednesday said it has received Fast Track Designation from the US health regulator for its investigational drug c...
- Zydus Cadila gets DCGI nod for world's first drug to treat liver diseaseThe Ahmedabad-based company said the approved product is the first ever drug anywhere in the world for treatment of Non-Cirrhotic Non-Alcoh...
- Zydus Cadila files NDA for Saroglitazar MagnesiumNASH is a progressive disease of the liver and a significant unmet medical need. There are currently no treatments available for the treatm...
- Zydus gets regulatory nod to market Lipaglyn in MexicoThe company has been granted marketing approval from the Mexican regulatory authority COFEPRIS to commercialise Lipaglyn in Mexico, Zydus s...
- Zydus gets USFDA nod for phase II trials of liver drugThis development underlines the group's commitment to bridging unmet healthcare needs with innovative therapies.
- US FDA pulls up Cadila for misbranding drugThe company has been researching on the drug to treat fatty liver disease or non-alcoholic steatohepatitis apart from diabetic dyslipidemia.
- Cadila Healthcare misbranded Saroglitazar, says US FDAIn a December 21 letter to the company, the US FDA has said the “broad statements” made by the company as the “world’s first” is misleading...
- Zydus gets USFDA nod for clinical trials of Sarolitazar"USFDA has endorsed company's plan to initiate a phase II clinical trial of Saroglitazar in patients with severe hypertriglyceridemia," Zyd...
- Indians face risk from unproven drugs with inadequate evidence of safety and efficacy, says medical journal"The pharmaceutical industry in India should face the same stringent regulations as elsewhere in the world, rather than continuing to allow...
Load More
